Skip to content
lifestyle.menstyle1.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nxera Pharma
Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
April 14, 2026
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
April 12, 2026
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
April 8, 2026
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
March 31, 2026
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
March 5, 2026
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
March 4, 2026
Nxera Pharma Proposes Changes to its Board of Directors
February 14, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
February 14, 2026
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
February 13, 2026
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
February 13, 2026
←
Previous Page
1
2